4569
Kyorin Pharmaceutical Co., Ltd.
2026/03/31
Kyorin Pharmaceutical has entered into a license agreement with BIODOL for the neuropathic pain treatment BDT272, acquiring exclusive rights in Japan, South Korea, and Taiwan. Payments up to 79 million euros are planned.
